Earnings Releases·Nov 3, 2026, 4:03 PM ET

Ardelyx — Third Quarter 2026 Earnings Summary

Total product revenue reached $125.5 million, a 19% year-over-year increase, driven by IBSRELA ($96.3 million, +23% YoY) and XPHOZAH ($29.2 million, +7% YoY), resulting in a narrowed net loss of $0.7 million compared to $1.0 million in the prior year period.
Full-year 2026 guidance was reiterated for IBSRELA ($350–$370 million), XPHOZAH ($110–$120 million), and operating expenses (below $500 million), while long-term targets remain focused on achieving $1 billion in annual IBSRELA revenue.
The Phase 3 ACCEL trial for chronic idiopathic constipation completed enrollment ahead of schedule, with topline data expected in the second half of 2027, alongside the upcoming issuance of a key U.S. patent covering commercial formulations for both products.
Cash and short-term investments increased to $285.3 million as of September 30, 2026, while long-term debt rose to $252.4 million, reflecting continued investment in R&D and commercial adoption efforts.